Man Group’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Man Group’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-38,145	Closed	-$5.77M	–	2366
2022 Q3	$5.77M	Buy	+38,145	New	+$5.65M	0.03%	684
2022 Q2	–	Hold	0	–	–	–	71
2021 Q3	–	Sell	-5,365	Closed	-$521K	–	2212
2021 Q2	$521K	Buy	+5,365	New	+$435K	﹤0.01%	1546
2020 Q3	–	Sell	-28,884	Closed	-$2.11M	–	1956
2020 Q2	$2.11M	Buy	+28,884	New	+$1.54M	0.01%	1047
2019 Q3	–	Sell	-217,868	Closed	-$9.54M	–	2051
2019 Q2	$9.54M	Buy	217,868 +169,384	+349%	+$9.55M	0.03%	651
2019 Q1	$2.5M	Buy	+48,484	New	+$2.09M	0.01%	1234

Other funds holding BHVN

LIP

Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

MSCM

McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

Man Group's BHVN Position: Q4 2022 in Review

Man Group sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 38,145 shares — an estimated $5.77M sold.

Man Group first reported a position in BHVN in Q1 2019 and held it in 5 quarters. The position peaked at $9.54M in Q2 2019. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

Man Group reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
Man Group sold 38,145 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $5.77M.
Man Group first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 5 quarters.
Man Group's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $9.54M in Q2 2019.
7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Man Group's 13F filing for Q4 2022, filed 14 Feb 2023.